These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29531000)

  • 1. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
    Ko DH; Hyun J; Kim HS; Park MJ; Kim JS; Park JY; Shin DH; Cho HC
    Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
    Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
    Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
    Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
    Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
    Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000.
    Ryu MR; Kang ES; Park HD
    J Clin Lab Anal; 2019 Jul; 33(6):e22921. PubMed ID: 31131509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II.
    Kinukawa H; Shirakawa T; Yoshimura T
    Clin Biochem; 2015 Nov; 48(16-17):1120-5. PubMed ID: 26297114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
    Qin X; Tang G; Gao R; Guo Z; Liu Z; Yu S; Chen M; Tao Z; Li S; Liu M; Wang L; Hou L; Xia L; Cheng X; Han J; Qiu L
    Int J Lab Hematol; 2017 Aug; 39(4):392-401. PubMed ID: 28318145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
    Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
    In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Han KH; Kim DY
    Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.
    Sohn A; Kim H; Yeo I; Kim Y; Son M; Yu SJ; Yoon JH; Kim Y
    J Pharm Biomed Anal; 2018 Jul; 156():142-146. PubMed ID: 29702392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of up-converting phosphor technology-based lateral flow assay for quantitative detection of serum PIVKA-II: Inception of a near-patient PIVKA-II detection tool.
    Huang Y; Zhang S; Zheng Q; Li Y; Yu L; Wu Q; Zheng J; Wu Y; Qiu F; Gao Q; Zhang J
    Clin Chim Acta; 2019 Jan; 488():202-208. PubMed ID: 30445030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
    Kawaguchi Y
    Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma.
    Choi J; Park Y; Kim JH; Kim HS
    Clin Biochem; 2011 Dec; 44(17-18):1464-8. PubMed ID: 21939644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma.
    Grosley BM; Hirschauer C; Chambrette B; Bezeaud A; Amiral J
    J Lab Clin Med; 1996 Jun; 127(6):553-64. PubMed ID: 8648260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
    Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
    Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.